Cancer Immunotherapy

News, research & analysis from the promising field of Cancer Immunotherapy, which involves treatments that harness and enhance the innate powers of the immune system to fight cancer.

April 12, 2017
GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote
Categories

GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote

[vc_row][vc_column][vc_column_text]GE Healthcare recently announced the acquisition of British cryogenic processing company Asymptote for an undisclosed price, strengthening its cell therapy portfolio with technologies designed to enable […]
Do you like it?
Read more
March 2, 2017
The Antibody Quality Conundrum: Abcam Ahead of the Curve with Knockout Validation
Categories

The Antibody Quality Conundrum: Abcam Ahead of the Curve with Knockout Validation

[vc_row][vc_column][vc_column_text] In September 2016 the International Working Group for Antibody Validation (IWGAV) finally announced their five conceptual pillars, outlining recommendations to mitigate the antibody specificity and […]
Do you like it?
Read more
January 12, 2017
Categories

Drug Development IPO Analysis: Over $4.2B Raised Globally in Q4 2016 Despite Continued NASDAQ Decline

[vc_row][vc_column][vc_column_text] Whilst the depression in the value and frequency of Drug Development IPOs on the NASDAQ market continued throughout the fourth quarter of 2016, a combined […]
Do you like it?
Read more
November 29, 2016
Categories

Promising Autologous CAR-T Cell Therapies Stumble: is this the End, or Just the Beginning?

[vc_row][vc_column][vc_column_text]The field of CAR-T immunotherapy presents a tantalising idea: reengineering a patient’s immune cells to attack cancer. CAR-T immunotherapy has the potential to revolutionise the way […]
Do you like it?
Read more
September 14, 2016
A Brief Timeline of Cancer Immunotherapy
Categories

Cancer Immunotherapy: A Developmental Timeline & Examination of the Prior Art Paradox

[vc_row][vc_column][vc_column_text]The American Society of Clinical Oncology (ASCO) recently named cancer immunotherapy as the 2016 Advance of the Year, with President Dr. Julie Vose noting that “no […]
Do you like it?
Read more
Prev page
1234
Next page